BRAF and neoplasm: Tumour-normal pairs were sequenced with a comprehensive cancer panel.<h4>Results</h4>30.1% of the tumours were classified as BRAF-mutated, 28.0% as RAS-, 18.1% as NF1-, and 23.8% as Triple-WT.